Corporate Overview Statutory Reports Financial Statements 255 Note 30.16 Interests in other entities (continued) (` cr) Summarised Statement of Profit and Loss Amal Ltd Amal Speciality Chemicals Ltd 2023-24 2022-23 2023-24 2022-23 Total income 33.37 43.19 57.86 23.06 Profit | (Loss) for the year 2.43 0.73 (1.94) (16.55) Other comprehensive income 0.00 0.03 (0.01) - Total comprehensive income 2.43 0.76 (1.95) (16.55) Profit allocated to NCI 1.22 0.38 (0.98) (8.30) (` cr) Summarised cash flows Amal Ltd Amal Speciality Chemicals Ltd 2023-24 2022-23 2023-24 2022-23 Cash flows from operating activities 1.67 (1.17) 9.08 (2.98) Cash flows from investing activities (2.76) (21.32) (3.32) (9.07) Cash flows from financing activities (0.01) 23.74 (5.65) 12.18 Net increase | (decrease) in cash and cash equivalents (1.10) 1.25 0.11 0.13 c ) Interests in associate and joint venture company accounted for using the equity method (` cr) Name of the entity Place of business | country of incorporation % of ownership interest Relationship Quoted fair value Carrying amount As at March 31, 2024 As at March 31, 2023 As at March 31, 2024 As at March 31, 2023 Rudolf Atul Chemicals Ltd India 50% Joint venture * * 27.10 20.37 Valsad Institute of Medical Sciences Ltd India 50% Associate * * 22.48 22.39 Total 49.58 42.76 *Note: Unlisted entity - no quoted price available Rudolf Atul Chemicals Ltd TheGroupacquired50%interest inRudolfAtul ChemicalsLtd (RACL), a joint venturecompany in Indiabetween IBIndustriechemie Beteiligungs GmbH (Germany) and Atul Ltd on August 18, 2011. RACL is engaged in the business of manufacturing and marketing textile chemicals. As per the contractual arrangement between the shareholders of RACL, both the companies have significant participating rights such that they jointly control the operations of the joint venture company. Valsad Institute of Medical Sciences Ltd Atul Healthcare Ltd (wholly-owned subsidiary of Atul Ltd) acquired shares in Valsad Institute of Medical Sciences Ltd (VIMS) for setting up a modern multi-speciality and super speciality NABH compliant 200-bed hospital in Valsad effective from October 04, 2022. The transaction has been entered by the Group, as promoters of VIMS are looking for strategic partner, to invest in VIMS for this project. i) Commitments and contingent liabilities in respect of the joint venture company (` cr) Particulars As at March 31, 2024 As at March 31, 2023 Share in contingent liabilities in respect of disputed demands for income tax 0.32 0.32 Share in capital commitments 0.01 0.05 Total commitments and contingent liabilities 0.33 0.37
RkJQdWJsaXNoZXIy MjA2MDI2